UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cell-free DNA (cfDNA) landscape in ERBB2 (HER2)-amplified Asian cancer patient population

Annals of oncology, 2018-11, Vol.29, p.ix114-ix115

2018

Volltextzugriff (PDF)

Circulating cell-free DNA molecular profiling among east Asian patients reveals activating MET alterations are common in diverse advanced cancer types

Annals of oncology, 2018-11, Vol.29, p.ix116-ix116

2018

Volltextzugriff (PDF)

RXDX-106 Is an orally-available, potent and selective TAM/MET inhibitor demonstrating preclinical efficacy in MET-dependent human malignancies

European journal of cancer (1990), 2016-12, Vol.69, p.S28-S29

2016

Volltextzugriff (PDF)

Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA)

Annals of oncology, 2018-10, Vol.29, p.viii223-viii223

2018

Volltextzugriff (PDF)

RXDX-105 demonstrates anti-tumor efficacy in multiple preclinical cancer models driven by molecular alterations in RET or BRAF oncogenes

European journal of cancer (1990), 2016-12, Vol.69, p.S35-S35

2016

Volltextzugriff (PDF)

40P Real-world clinical genomic analysis of patients with BRAF mutated cancers identifies BRAF class II and III as a population of unmet medical need

Annals of oncology, 2022-03, Vol.33, p.S18

2022

Volltextzugriff (PDF)

373PCell-free DNA (cfDNA) landscape in ERBB2 (HER2)-amplified Asian cancer patient population

Annals of oncology, 2018-11, Vol.29 (suppl_9)

2018

Volltextzugriff (PDF)

Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer

Cancer research (Chicago, Ill.), 2005-06, Vol.65 (12), p.5221-5230

2005

Volltextzugriff (PDF)

Abstract P3-06-05: Not presented

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P3-P3-06-05

2018

Volltextzugriff (PDF)

65 - RXDX-106 Is an orally-available, potent and selective TAM/MET inhibitor demonstrating preclinical efficacy in MET-dependent human malignancies

European journal of cancer (1990), 2016-12, Vol.69, p.S28-S29

2016

Volltextzugriff (PDF)

378PCirculating cell-free DNA molecular profiling among east Asian patients reveals activating MET alterations are common in diverse advanced cancer types

Annals of oncology, 2018-11, Vol.29 (suppl_9)

2018

Volltextzugriff (PDF)

Somatic mutations in BRCA2, NFE2L2, ARID1A and NOTCH1 sensitize to anti-PDL1 therapy in multiple tumor types

Annals of oncology, 2018-12, Vol.29, p.x1-x1

2018

Volltextzugriff (PDF)

Determinants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T)

Annals of oncology, 2019-10, Vol.30, p.v485

2019

Volltextzugriff (PDF)

1189PD - Determinants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T)

Annals of oncology, 2019-10, Vol.30, p.v485-v485

2019

Volltextzugriff (PDF)

1189PDDeterminants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

INHIBITION OF HIF-2 alpha PREVENTS TUMORIGENESIS

Anticancer research, 2008-10, Vol.28 (5C)

2008

Volltextzugriff (PDF)

Hypoxia Inducible Factor Activates the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma Cells

The Journal of biological chemistry, 2003-11, Vol.278 (45), p.44966-44974

2003

Volltextzugriff (PDF)

2OSomatic mutations in BRCA2, NFE2L2, ARID1A and NOTCH1 sensitize to anti-PDL1 therapy in multiple tumor types

Annals of oncology, 2018-12, Vol.29 (suppl_10)

2018

Volltextzugriff (PDF)

662PBiomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

85 - RXDX-105 demonstrates anti-tumor efficacy in multiple preclinical cancer models driven by molecular alterations in RET or BRAF oncogenes

European journal of cancer (1990), 2016-12, Vol.69, p.S35-S35

2016

Volltextzugriff (PDF)

ETS-1 ONCOGENIC ACTIVITY IS MEDIATED VIA TGF alpha

Anticancer research, 2008-10, Vol.28 (5C)

2008

Volltextzugriff (PDF)

Hypoxia Inducible Factor Activates the Transforming Growth Factor- alpha /Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL super(-/- ) Renal Cell Carcinoma Cells

The Journal of biological chemistry, 2003-11, Vol.278 (45), p.44966-44974

2003

Volltextzugriff (PDF)

Education of rheumatic patients (author's transl)

Liječnički vjesnik, 1980-07, Vol.102 (7-8), p.349

Franovic, A

1980

Volltextzugriff (PDF)

The rheumatic patient - an equal member of his rehabilitation team

Reumatizam, 1981, Vol.28 (1), p.1

Franovic, A

1981

Volltextzugriff (PDF)

How Do Instructors Explain The Mechanism by which ATP Drives Unfavorable Processes?

CBE life sciences education, 2023-12, Vol.22 (4), p.ar50-ar50

2023

Volltextzugriff (PDF)

1 – 25 von 198

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(160)
Mit Volltextzugriff
(158)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(181)
Croatian
(18)
Deutsch
(1)
Serbian
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(89)
Physical Sciences
(46)
Physics
(46)
Humans
(45)
Physics, Mathematical
(34)
Life Sciences & Biomedicine
(29)
Mathematics
(26)
Mathematics, Applied
(17)
Female
(15)
Physics, Fluids & Plasmas
(15)
Physics, Multidisciplinary
(15)
Orthopedics
(14)
Cell Line, Tumor
(13)
Mathematics, Interdisciplinary Applications
(13)
Tumors
(13)
Technology
(12)
Animals
(11)
Middle Aged
(11)
Cancer
(10)
Male
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Cell-free DNA (cfDNA) landscape in ERBB2 (HER2)-amplified Asian cancer patient population

Circulating cell-free DNA molecular profiling among east Asian patients reveals activating MET alterations are common in diverse advanced cancer types

RXDX-106 Is an orally-available, potent and selective TAM/MET inhibitor demonstrating preclinical efficacy in MET-dependent human malignancies

Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA)

RXDX-105 demonstrates anti-tumor efficacy in multiple preclinical cancer models driven by molecular alterations in RET or BRAF oncogenes

40P Real-world clinical genomic analysis of patients with BRAF mutated cancers identifies BRAF class II and III as a population of unmet medical need

373PCell-free DNA (cfDNA) landscape in ERBB2 (HER2)-amplified Asian cancer patient population

Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer

Abstract P3-06-05: Not presented

65 - RXDX-106 Is an orally-available, potent and selective TAM/MET inhibitor demonstrating preclinical efficacy in MET-dependent human malignancies

378PCirculating cell-free DNA molecular profiling among east Asian patients reveals activating MET alterations are common in diverse advanced cancer types

Somatic mutations in BRCA2, NFE2L2, ARID1A and NOTCH1 sensitize to anti-PDL1 therapy in multiple tumor types

Determinants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T)

1189PD - Determinants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T)

1189PDDeterminants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T)

INHIBITION OF HIF-2 alpha PREVENTS TUMORIGENESIS

Hypoxia Inducible Factor Activates the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma Cells

2OSomatic mutations in BRCA2, NFE2L2, ARID1A and NOTCH1 sensitize to anti-PDL1 therapy in multiple tumor types

662PBiomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA)

85 - RXDX-105 demonstrates anti-tumor efficacy in multiple preclinical cancer models driven by molecular alterations in RET or BRAF oncogenes

ETS-1 ONCOGENIC ACTIVITY IS MEDIATED VIA TGF alpha

Hypoxia Inducible Factor Activates the Transforming Growth Factor- alpha /Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL super(-/- ) Renal Cell Carcinoma Cells

Education of rheumatic patients (author's transl)

The rheumatic patient - an equal member of his rehabilitation team

How Do Instructors Explain The Mechanism by which ATP Drives Unfavorable Processes?

Suchergebnisse filtern